Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 11/20 | 0.54 |
| ▸ | PRKCB | P05771 | 10/20 | 0.54 |
| ▸ | GSK3B | P49841 | 9/20 | 0.54 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.54 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.51 |
| ▸ | PRKCH | P24723 | 3/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.47 |
| ▸ | PRKCG | P05129 | 5/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069262 | 0.86 | GSK3B (0.71) | PRKCAPRKCBGSK3BCAMK2DPRKCD | |
| SCHEMBL2955240 | 0.83 | GSK3B (0.57) | PRKCAPRKCBGSK3BPRKCDPRKCG | |
| SCHEMBL1128590 | 0.80 | GSK3B (0.55) | PRKCAPRKCBGSK3BCAMK2DIDH1 | |
| SCHEMBL8161830 | 0.76 | CCNE2 (0.81) | PRKCAPRKCBGSK3BPRKCDPRKCH | |
| SCHEMBL1127687 | 0.76 | GSK3B (0.64) | PRKCAPRKCBGSK3BCAMK2DIDH1 | |
| SCHEMBL4682932 | 0.76 | GSK3B (0.67) | PRKCAPRKCBGSK3BCAMK2DPRKCD | |
| SCHEMBL13670446 | 0.74 | GSK3B (0.65) | PRKCAPRKCBGSK3BCAMK2DPRKCD | |
| SCHEMBL1127716 | 0.73 | GSK3B (0.64) | PRKCAPRKCBGSK3BPRKCDPRKCG | |
| SCHEMBL3774109 | 0.73 | GSK3B (0.66) | PRKCAPRKCBGSK3BCAMK2DPRKCD | |
| SCHEMBL3774763 | 0.73 | PRKCA (0.85) | PRKCAPRKCBGSK3BCAMK2DPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| EP-1513520-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2004-03-18 | — | — | US | disclosed |
| WO-2003103663-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885 |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.